Inpharmus
Turkey - Istanbul
ICOSAPENT ETHYL (icosapent ethyl) by Inpharmus is low-density lipoprotein triglycerides (vldl-tg) synthesis and/or secretion and enhances tg clearance from circulating vldl particles. First approved in 2021.
Drug data last refreshed 18h ago
low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver;…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
Worked on ICOSAPENT ETHYL at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.